In this issue:
Better oncological outcomes with RARP vs ORP?
Declines in prostate cancer screening and early-stage disease
Prostate-specific α-antagonists increase risk of falls
Survival compared with EBRT vs EBRT + brachytherapy
Treatment options in previously treated advanced RCC - nivolumab or cabozantinib vs everolimus
Please login below to download this issue (PDF)